Ligand Pharmaceuticals (LGNDV) Stock Analysis

What Ligand Pharmaceuticals does

Ligand Pharmaceuticals Incorporated is a biopharmaceutical entity dedicated to sourcing and developing innovative technologies that empower global pharmaceutical companies in their quest to discover and bring new medications to market. The company's diverse commercial portfolio features prominent treatments such as Kyprolis and Evomela, both prescribed for multiple myeloma; Veklury, addressing moderate or severe COVID-19; and a Teriparatide injection product for osteoporosis management. Their infectious disease arsenal includes Vaxneuvance, designed to prevent invasive illnesses caused by Streptococcus pneumoniae, and Pneumosil, a crucial pneumococcal conjugate vaccine combating pneumococcal pneumonia in pediatric populations. Furthermore, Ligand offers Rylaze, a recombinant erwinia asparaginase, indicated for treating acute lymphoblastic leukemia or lymphoblastic lymphoma in both adult and younger patients. The company leverages its proprietary Captisol technology in several key products: Nexterone, an amiodarone formulation; Zulresso, a brexanolone formulation for postpartum depression; and Noxafil-IV, an intravenous posaconazole formulation. Other notable products include Duavee for postmenopausal osteoporosis, the Aziyo portfolio encompassing commercial pericardial repair and CanGaroo envelope extracellular matrix products, Exemptia for autoimmune conditions, Vivitra for breast cancer, Bryxta and Zybev for a range of therapeutic areas, and Minnebro for hypertension. Beyond its direct product sales, Ligand also has a robust pipeline of partnered and licensed programs undergoing clinical development, targeting significant therapeutic areas such as various cancers, seizure disorders, diabetes, cardiovascular diseases, muscle wasting, liver and kidney ailments, and other medical conditions. Additionally, the company is a supplier of Captisol materials. Established in 1987, Ligand Pharmaceuticals is headquartered in San Diego, California.

Key metrics

ETFs linked to LGNDV

Broad-market and Healthcare sector ETFs an investor holding Ligand Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how LGNDV fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Ligand Pharmaceuticals?

Ligand Pharmaceuticals trades under the ticker LGNDV on NASDAQ.

Which exchange is LGNDV listed on?

LGNDV is listed on NASDAQ.

What sector does Ligand Pharmaceuticals operate in?

Ligand Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze LGNDV in a portfolio?

PortView shows LGNDV's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.